AtriCure, Inc. vs Pfizer, Inc. — Stock Comparison

ATRC
AtriCure, Inc.
$29.02
▲ 3.24%
vs
PFE
Pfizer, Inc.
$26.33
▼ 1.39%
Q·Score Winner
AtriCure, Inc.
ATRC6.7/10vs 6.5/10

Q·Score Breakdown

6.7
Neutral
Overall
6.5
Neutral
3.7
Quality
7.4
9.7
Health
7
7.5
Growth
5.6
6.3
Valuation
6.7
7.4
Sentiment
5.2
ATRC

Clean balance sheet with low leverage (0.2× debt-to-equity).

currently unprofitable (-2% margin).

PFE

Strong profitability with 12% net profit margins.

analyst sentiment is cautious.

Analyst Consensus

BUY
Target $46.75 (+61.1%)
8 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts

Fundamentals

ATRC
PFE
Trailing P/E
19.4×
78.5×
Forward P/E
9.4×
-2.1%
Profit Margin
12.4%
75.0%
Gross Margin
75.8%
-2.4%
ROE
8.9%
13.1%
Revenue Growth
-1.2%
Earnings Growth
1.43
Beta
0.39
Price / Book
$1.5B
Market Cap
$149.8B
$27 – $43
52-Week Range
$22 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →